Cardinal Health raises FY2027 EPS outlook after strong Q1 results

Based on reporting by Cardinal Health, Inc. (PR Newswire).

Cardinal Health (NYSE: CAH) announced first‑quarter fiscal 2027 results on Nov. 5, 2026, showing a 5% rise in revenue to $67.5 billion and a 13% increase in GAAP operating earnings to $753 million. The company used the strong performance to lift its full‑year non‑GAAP earnings‑per‑share (EPS) outlook to $12.80‑$13.00, up from the prior $12.40‑$12.60 range.

What happened

Key figures from the PR Newswire release include:

• Revenue: $67.5 billion, up 5% YoY.
• GAAP operating earnings: $753 million, up 13%.
• GAAP diluted EPS: $2.38, up 27%.
• Non‑GAAP operating earnings: $1.0 billion, up 17%.
• Non‑GAAP diluted EPS: $3.26, up 28%.
• Pharmaceutical & Specialty Solutions revenue: $62.6 billion, up 6%.
• Pharmaceutical & Specialty Solutions profit: $783 million, up 17%.
• Global Medical Products & Distribution revenue: $3.2 billion, flat YoY.
• Global Medical Products profit: $33 million, down.
• Other segment revenue: $1.8 billion, up 7%.
• Other segment profit: $193 million, up 16%.

CEO Jason Hollar said the results “demonstrate consistent execution against our strategic priorities” and justified raising the non‑GAAP EPS outlook.

Why it matters

Cardinal Health is the second‑largest drug distributor in the United States, with a 2026 revenue base of roughly $60.7 billion. Even modest percentage gains translate into hundreds of millions of dollars at the bottom line, which can shift market sentiment for the entire wholesale‑distribution sector.

Analysts highlighted two implications:

1. Benchmark for peers. Rivals such as Cencora and McKesson will be measured against Cardinal’s upgraded guidance. A failure to meet or exceed the new range could be viewed as a relative weakness.
2. Investor confidence. The stock rose to a 52‑week high of $262.01, closing at $253.71—about 1.73% above the October 20 peak. The intraday climb of roughly 4% added about $2.2 billion to the company’s market value, underscoring how earnings beats can quickly lift valuation.

In addition, Cardinal secured a binding letter of intent to renew its distribution agreements with CVS Health, removing a major customer‑concentration risk that had previously weighed on the stock.

What it means for investors

For readers who follow the markets but aren’t finance specialists, the practical takeaways are:

• Higher earnings target. The new non‑GAAP EPS range of $12.80‑$13.00 suggests the company expects stronger profitability for the rest of the fiscal year.
• Potential upside. The share price already reflected the earnings beat, but the guidance lift leaves room for further upside if the back half of the year matches or exceeds expectations.
• Risk considerations. The guidance is non‑GAAP, meaning it excludes certain costs and tax effects. Investors should compare it with GAAP figures and understand the adjustments.
• Sector dynamics. A stronger Cardinal can set a higher bar for other distributors, influencing relative performance assessments across the industry.

Readers who want to dig deeper into how earnings releases are structured can consult our beginner’s guide to reading an earnings report.

What to watch next

Key events that could shape Cardinal Health’s trajectory include:

1. The upcoming second‑quarter earnings release, which will reveal whether the back‑half assumptions that underpin the guidance raise hold true.
2. Progress on the CVS Health distribution renewal, as any changes to the agreement could affect revenue stability.
3. Performance of the Pharmaceutical & Specialty Solutions segment, especially brand and specialty drug sales, which drove most of the revenue growth.
4. Market reaction to peers’ earnings, particularly Cencora and McKesson, to see if Cardinal’s raise creates a broader sector rally.

Analysts will also monitor any updates to the company’s non‑GAAP adjustments, as those can affect the comparability of future results.

Sources

• Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook — reported by Cardinal Health, Inc., PR Newswire
• Cardinal Health raises fiscal 2027 EPS outlook after a strong first quarter — 24/7 Wall St.
• Cencora (COR) Drops 4% While Rival Cardinal Health Posts a Beat — 24/7 Wall St.